Jan 18 (Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.
The settlement was disclosed on Tuesday in papers filed in federal court in Connecticut. The company did not admit to wrongdoing. (Reporting by Jody Godoy; Editing by Noeleen Walder, Editing by Franklin Paul)
